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Purpose: We reviewed our experience with a clinical pathway instituted in December 1993 
for all nonurgent abdominal aortic aneurysm (AAA) surgery. 
Methods: We analyzed a reference group of  49 consecutive pre-pathway AAA patients 
(group I) and the 44 patients enrolled in the first year of  the pathway (group II). On the 
basis of  the interim review of  data collected uring the first year, pathway modifications 
were made, and 34 patients enrolled after these modifications (group I I I )  were also 
analyzed. 
Results: Comparison of  groups I and I I  showed that institution of  the pathway resulted in 
a marginally significant reduction in mean charges of  14.7% (p -- 0.09), and a slight fall in 
mean length of  stay (LOS) (13.8 vs 13.1 days, NS) and mortality rate (4.1% vs 2.3%, NS). 
For group II, a significant correlate (p < 0.05) of  increased charges was fluid overload as 
diagnosed by chest radiograph. This recognition led to active efforts o reduce perioper- 
ative fluid administration. Comparison of  groups I I  ~nd I I I  revealed that the practice 
modifications led to marked reduction in the incidence of fluid overload (73% vs 24%; p < 
0.01), mean charges (30.4% reduction; p < 0.05), mean LOS (13.1 vs 10.2 days; p < 
0.05), and median LOS (11 vs 8 days). Multiple regression analysis of  all pathway 
patients showed that preoperative renal insufficiency is a significant predictor of  both 
increased LOS (p < 0.01) and charges (p < 0.01), but that age, sex, and coronary disease 
were not predictive. Of  the postoperative parameters analyzed, important correlates of  
increased charges were acute renal failure (p < 0.01 ) and fluid overload (p < 0.01). 
Conclusions: Institution of  a clinical pathway for AAA repair resulted in significant charge 
reduction and a slight reduction in stay. Practice modifications based on interim data 
analysis yielded further significant reductions in charges and LOS, with overall per- 
patient charge savings (group I vs I I I )  of  40.6% (p < 0.05) and overall LOS reduction of  
3.5 days (p < 0.05). The reduction in actual charges was seen despite an overall increase in 
the hospital rate structure. Comparing roups I, I I ,  and I I I ,  we found no indication of  
increasing mortality rate. Ongoing analysis has identified correlates of  increased charges, 
potentially permitting identification of  high-cost subgroups and more focused cost- 
control efforts. Rather than restricting management, clinical pathways with periodic data 
analysis may improve quality of  care. (J Vase Surg 1997;25:84-93.) 
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Of  the many recent changes in health care in the 
United States, one of  the most prominent has been 
the increasing use of  clinical pathways and case man- 
agement. Pathways provide a standardized diagnosis- 
specific multidisciplinary care plan, and case manage- 
ment involves a focused effort to optimize resource 
utilization for each patient. 
The driving force behind these changes has been 
the need for hospitals to remain financially competi- 
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rive in an era of managed care and capitation. M- 
though an extensive body of literature describes de- 
velopment of pathways in a variety of clinical settings, 
definitive study of the impact of clinical pathways has 
been more limited, especially in the area of vascular 
surgery. Available reports examining major vascular 
procedures 1 and abdominal aortic aneurysm (AAA) 
operations 2 have not definitively shown an economic 
benefit of pathway implementation when both inpa- 
tient and outpatient costs are considered. 
In addition to cost savings, another potential 
benefit of pathways and case management is im- 
provement in quality of care. Although it has been 
argued that reduction ofvariati0n in the provision of 
a service is the most effective way to improve quality, 3
there is a legitimate concern that inflexible care plans 
and the cost-reduction focus of pathways may lead to 
reduced quality of care. The issue has not been defin- 
itively resolved. 
We report herein our experience with a clinical 
pathway and case management for elective AAA sur- 
gery instituted in 1993. We have studied the impact 
of these changes on resource utilization and clinical 
outcomes, as well as on our ability to improve quality 
of care in this group of patients. 
MATERIALS AND METHODS 
Pathway implementation. Pathway develop- 
ment at University of Pittsburgh Medical Center 
(UPMC) began in the early 1990s because of a major 
hospital-wide initiative. The AAA pathway was devel- 
oped by an 16-member committee chaired by a vas- 
cular surgeon. Other members included a case man- 
ager and representatives from hospital administration 
and nursing. After a 2-month development phase 
and approval by the medical executive committee, 
the pathway and case management were instituted in 
December 1993, and more than 97% of all elective 
infrarenal AAA patients since then have been en- 
rolled. The only exclusion criteria were another 
planned major surgical procedure performed simul- 
taneously with the AAA surgery, and recurrent AAA 
above a previous repair. Enrollment in the pathway 
led to the application of a standardized, multidisci- 
plinary care plan. A case manager monitored each 
enrolled patient o ensure compliance and facilitate 
discharge planning. However, variation from the 
standard care plan was permitted whenever necessary 
in the judgment of the responsible attending or 
house officer. An important aspect of pathway in- 
stitution at UPMC is review Of outcome data and 
modification of  the pathway, if needed. Such a 
review was undertaken 1 year after pathway imple- 
First review of data 
Pathwa~instituted Pathway modified 
] Group I(n=49) t Group II (n=44) ] Group III (n=34) 
FEB '93 DEC '93 NOV '94 OCT '95 
Fig. 1. Patient groups in relation to institution of path- 
way and pathway modifications. 
mentation, and modifications were made, as de- 
tailed later. 
UPMC clinical case managers generally have ei- 
ther a baccalaureate or masters degree in nursing, 
and their salaries are paid by the hospital. The case 
manager salary was not factored in our calculations of 
the fiscal impact of pathway implementation. How- 
ever, it is noteworthy that the clinical case manager 
for vascular surgery was also responsible for other 
surgical services, including the large renal transplant 
service. Therefore, the impact of factoring in her 
salary would be quite small. 
Patient groups. Applying the exclusion criteria 
cited above for the pathway patients, we identified a
reference group of 49 consecutive inffarenal AAA 
patients treated immediately before pathway imple- 
mentation (group I) (Fig. 1). The 44 patients en- 
rolled in the first year of the pathway were studied 
(group II), along with 34 consecutive patients en- 
rolled immediately after the pathway modifications 
were made (group III). Our series includes patients 
transferred to our service directly from another insti- 
tution, as well as some patients who were admitted 
initially to another service within our hospital and 
then transferred to our service for same-stay AAA 
repair. We designated all such patients as trans- 
ferred patients. Group I included 11 transferred 
patients, and groups II and III each contained nine 
transferred patients. In all cases, length of stay 
(LOS) was measured from the date of admission to 
our hospital. 
Data collection and analysis. Demographic, 
clinical, and resource utilization data were collected 
from UPMC's computerized medical record and fis- 
cal data base. Elements of patients' medical history 
that were not available in the database were obtained 
by direct chart review. Statistical analysis was per- 
formed using a spreadsheet program (Excel) and a 
statistical package (GB Stat) on a personal computer. 
Hospital charges are presented in relative terms, us- 
ing group I charges as a baseline of 100%, in compli- 
ance with hospital policy. 
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Table I. Comparison of demographic and 
clinical features 
Group I Group II  Group II I  
Parameter (n = 49) (n = 44) (n = 34) 
Age (years) 70.6 69.9 72.2 
Sex (% female) 26.5% 20.5% 32.4% 
History of 
Coronary artery disease 57.1% 54.5% 67.6% 
Coronary bypass 20.4% 22.7% 26.5% 
Pulmonary dysfunction 32.7% 34.1% 41.2% 
Liver dysfunction 2.0% 9.1% 2.9% 
Smoking history 77.6% 84.1% 79.4% 
Renal dysfunction 6.1% 11.4% 8.8% 
Diabetes 20.4% 25.0% 14.7% 
Hypertension 67.3% 63.6% 58.8% 
Group I, pre-pathway reference group; group II, patients enrolled 
during first year of pathway; group III, patients enrolled after 
pathway modifications. No significant differences among groups 
in any of the parameters, by X 2 testing. 
RESULTS 
Table I shows demographic and clinical charac- 
teristics of the patient groups. Patients were predom- 
inantly male, with a mean age near 70 years. Clinical 
features were typical of AAA patients in many large 
series. There were no statistically significant differ- 
ences between groups for any of the parameters, by 
X 2 analysis. 
To assess the initial effects of pathway implemen- 
tation, we compared groups I and II. Fig. 2 shows a 
marginally significant decrease in relative mean 
charges (100% to 85.7%; p = 0.09), as well as a slight 
decrease in mean length of hospital stay (13.8 to 
13.1 days; NS). Median charges also fell (100% to 
93%), and there was no change in median LOS (11 
days). There was no significant change in 30-day 
operative mortality or 30-day readmission rates. 
At the 1-year pathway review (November 1994) 
several postoperative parameters in group II patients 
were examined for correlation with charges and 
LOS: myocardial infarction, arrhythmia, fluid over- 
load, gastrointestinal bleeding, acute renal failure, 
and ileus. As shown in Fig. 3, the sole parameter 
found to correlate significantly (p < 0.05) with in- 
creased charges and LOS was fluid overload, defined 
as moderate or severe pulmonary vascular congestion 
by chest roentgenogram (CXR) on postoperative day 
1 or 2. The CXR criterion was used to define fluid 
overload because of its relative objectivity in compar- 
ison with clinical criteria for fluid overload, and its 
ease of retrieval from the medical database. The fluid 
overload data led us to initiate a multidisciplinary 
effort (surgery, anesthesiology, and critical care ser- 
vices) to reduce perioperative fluid administration. 
These changes were facilitated by the fact that the 
anesthesia and critical care services were directly in- 
volved in the AAA-pathway committee. Other 
changes were also made to the pathway: reduction in 
the number of units of blood set up for AAA patients 
from 6 to 4, because no more than 4 units had ever 
been necessary in group II; and streamlining of the 
process of arranging preadmission local accommoda- 
tions for same-day surgery patients who lived more 
than 3 hours distant from UPMC. 
The effect of the pathway modifications was as- 
sessed by comparing roups II and III. As Fig. 4 
shows, there was a sharp decrease in the incidence of 
fluid overload (73% vs 23%; i0 < 0.01) and mean 
intensive care unit (ICU) stay (4.3 vs 2.6 days; p < 
0.05). In addition, relative mean charges decreased 
significantly (85.7% vs 60%; p < 0.05), as did mean 
LOS (13.1 vs 10.2 days; p < 0.05). Reductions in 
median charges (93% vs 77%) and median LOS (11 
vs 8 days) were also observed. A slight fall in mortal- 
ity rate and a small increase in readmission rate were 
not significant. The mortality and readmission rate 
differences between groups I and III were also not 
significant. 
The 29 transferred patients (as defined in the 
Methods ection) had a longer LOS than the patients 
who were directly admitted from an outpatient set- 
ting (17.1 vs 11.1 days; p < 0.01). Virtually all of this 
difference was attributable to a longer preoperative 
stay for the transferred patients (6.2 vs 0.7 days; p < 
0.001). There was no significant difference between 
groups I, II, and III with respect to the preoperative 
LOS (2.1 vs 1.9 vs 1.7 days; NS), indicating that the 
impact of the transferred patients was equivalent in 
all three patient groups. 
Further analysis has included multiple linear re- 
gression analysis of data for all pathway patients 
(groups II and Ill) to identify parameters that corre- 
late with increascd resource utilization and adverse 
events. We examined both preoperative variables 
(age, sex, coronary, artery disease, pulmonary dis- 
ease, smoking, diabetes, hypertension, and chronic 
renal insufficiency), and the postoperative variables 
(enumerated above in the description of the 1-year 
pathway review). The sole preoperative parameter 
that was predictive (p < 0.01) of increased charges 
and LOS was chronic renal insufficiency (preopera- 
tive serum creatinine level >2.0 mg/dl).  The two 
postoperative parameters that correlated (p < 0.01) 
with increased charges were fluid overload (as ex- 
pected), and acute renal failure (any postoperative 
serum creatinine levation of 0.5 mg/dl  over the 
preoperative l vel). Interestingly, preoperative r nal 
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Fig. 2. Impact of pathway implementation: comparison of Groups I and II (see text for 
details). *Difference from group I marginally significant (p = 0.09). 
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Fig. 3. Importance in group II of volume overload by CXR. *Significant difference between 
groups (p < 0.05). 
insufficiency did not correlate with development of  
postoperative acute renal failure. 
DISCUSSION 
Adapted from other fields such as engineering, 
pathways in health care were used initially to simplify 
documentation and to reduce variation in nursing 
care. Economic pressures have led hospitals to ex- 
pand the scope of pathways to include the entire 
treatment process for selected patient groups. By 
delineating the processes of  care for a typical patient, 
pathways theoretically allow hospitals to better pre- 
dict the costs associated with a particular patient 
subset. 4 This is an important consideration i  the 
current era of capitation and managed care. How- 
ever, the chief economic benefit of  pathways i reduc- 
tion of cost by formulating a standard care plan that 
minimizes unnecessary resource use. 3-s In general, 
case management has proven to be a crucial adjunct 
to pathways, to ensure compliance with the case plan 
and to facilitate patient discharge. The utility of  this 
approach in reduction of resource utilization has 
been demonstrated for pneumonia, 6 thoracotomy, 7 
acute leukemia, 8 cardiac surgery, 9-n and stroke? 2
Despite previous reports about vascular surgery path- 
ways, 1,2,1s definitive demonstration f a reduction in 
resource consumption is lacking. 
An additional unresolved issue is the relationship 
between pathways and quality improvement. Cost- 
focused pathways, with emphasi  on reduced hospital 
stays and potential loss of physician independence, 
may conceivably result in reduced quality and more 
readmissions. However, it has been speculated that 
standardization of medical care is a key aspect of 
quality improvement, s,s,14 The few studies that have 
critically examined this question have found that 
pathways help the process of quality improve- 
ment.7,11,12 
In this study, we found that institution of a path- 
way and case management for AAA surgery was fol- 
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Fig. 4. Impact of pathway implementation a d interim changes in pathway: comparison of 
groups I, II, and III (see text for details). &, Difference from group I marginally significant (p = 
0.09); *, value significantly different from group I value (p ~ 0.05); #, value significantly 
different from group II value (p ~ 0.05); ns, value not significantly different from group I value; 
n/a, data not available for group I. 
lowed by a marginally significant (p = 0.09) reduc- 
tion in mean hospital charges (15% reduction) and a 
nonsignificant reduction in mean length of stay (Fig. 
2). Although this was not a randomized controlled 
study, the control group (group I) was a consecutive 
series of patients treated just before institution of the 
new measures, and groups I and II had very similar 
demographic and clinical characteristics. Thus it 
seems likely that the pathway and case management 
implementation caused the observed decrease in 
charges. The lack of significant decrease in LOS with 
initial pathway implementation may reflect the fact 
that our service had initiated same-day AAA admis- 
sion and early discharge planning even before path- 
way implementation. Of importance is that pathway 
institution did not result in any significant change in 
mortality or readmission rate (Figs. 2 and 4). In this 
series, the number of patients who required readmis- 
sion was small, and evaluation of a larger series of 
patients may be necessary to document whether de- 
creasing LOS is associated with increase in readmis- 
sion rates. 
In addition to studying the initial impact of the 
pathway, we studied quality improvement in the set- 
ting of the new care mechanisms. Collection of clin- 
ical outcome data was believed to be as important as 
collection of fiscal data with implementation f path- 
ways at UPMC. The clinical data included anumber 
of preoperative risk factors and postoperative end- 
points. The existence of a centralized computerized 
clinical database aided this process greatly. Data anal- 
ysis 1 year after pathway implementation showed 
that the finding of pulmonary vascular congestion by 
CXR correlated strongly (p ~ 0.05) with increased 
• charges and LOS (Fig. 3). We used the endpoint of 
vascular congestion on CXR because this was more 
reproducible and easily retrieved than the clinical 
diagnosis of pulmonary edema. Only a few high-risk 
patients had pulmonary artery catheters, o cardiac 
filling pressure data were not appropriate as criteria 
for fluid overload. We speculated that volume over- 
load was contributing to delayed extubation, pro- 
longed intensive care unit (ICU) stay, and increased 
charges. Therefore, a multidisciplinary effort to re- 
duce postoperative fluid administration was initiated. 
The anesthesia and critical care services played a cen- 
tral role in instituting the desired changes in fluid 
management. Because these services had been ac- 
tively involved from the beginning in the AAA path- 
way committee, it was not difficult to bring about 
these changes. The change in fluid administration 
philosophy, along with other minor pathway changes 
(see Results section), was followed by sharp declines 
in the incidence of volume overload, ICU stay, as 
well as mean LOS and mean charges (Fig. 4). 
Because group II and III patients had very similar 
demographic and clinical features, our data suggest 
that the pathway modifications led directly to the 
beneficial changes in fiscal and clinical endpoints. We 
noted also in comparing roups I, II, and III that the 
trends in median charges (100% vs 93% vs 77%) and 
median LOS (11 vs 11 vs 8 days) closely paralleled 
the changes in the means. This suggests that the data 
were not skewed by a few outliers. 
The relationship between hospital charges and 
actual costs is a highly complex one, because of issues 
such as how to incorporate fixed costs. At our insti- 
tution, there is currently insufficient accounting data 
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to allow accurate calculation of actual costs for an 
individual patient. The Medicare cost-to-charge ratio 
has been used by some authors, but its utility has 
been questioned, is Following the example of other 
authors,  1°'12-16 we used hospital charges as a proxy 
for actual costs. Between February 1993 and Decem- 
ber 1995, there was an overall increase of 5% in 
hospital charges for most services. Therefore, the 
reductions observed in patient charges ubsequent to
pathway introduction are actually understated. We 
elected not to adjust charge values for the inflation 
because of the complexities of adjusting for different 
percentage increases in different types of services, and 
because of difficulties in determining when various 
charge increases were applied. Any such adjustment 
would only have strengthened our conclusions about 
charge reductions after pathway implementation. 
As in other tertiary care centers, we treat many 
patients who are transferred from other institutions. 
The mean LOS was markedly greater for transferred 
patients (17.1 vs 11.1 days), and this difference was 
almost entirely attributable to prolongcd preopera- 
tive stay (6.2 vs 0.7 days) for these patients. Thus the 
transferred patients do not have a prolonged postop- 
erative course, but their LOS is increased by preop- 
erative factors uch as medical evaluation and sched- 
uling constraints. These factors are often beyond the 
control of the vascular surgeon. 
In this consecutive series of AAA patients, the 
overall mortality rate was only 2.4% (three deaths out 
of 127 patients). Contrary to the notion that path- 
way implementation may lead to reduced quality of 
care, we observed (Fig. 4) a nonsignificant trend 
toward decreased mortality rates in groups I, II, and 
III (4.5% vs 2.3% vs 0%). 
The pathway and case management mechanisms 
were not essential per se for the collection and anal- 
ysis of outcome data. However, the decision to focus 
on outcomes, and the help of the case manager to 
collect data (both of which accompanied pathway 
implementation), were vital. 
Further analysis of the pathway patients (groups 
II and III) reveals a potentially important predictor 
of high resource utilization (i.e., preoperative r nal 
insufficiency) and another postoperative correlate of 
increased charges (i.e., acute renal failure). These 
data will allow us to focus future cost control and 
quality improvement efforts. 
It is important to note that pathway design, areas 
for potential quality improvement, and the magni- 
tude of achievable gains in resource use are likely to 
be highly institution-specific. 
CONCLUSION 
On the basis of our experience with patients un- 
dergoing AAA repair, we conclude that implementa- 
tion of a pathway and case management can lead to 
significant reductions in resource consumption with- 
out significant change in mortality and rcadmission 
rates. Rather than restricting management decisions, 
clinical pathways with periodic review of outcome 
data can result in quality improvement. 
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DISCUSSION 
Dr. George Andros (Encino, Calif.). The convulsive 
changes that now strain the American health care system to 
the breaking point are driven by macroeconomics. Our 
society, and in particular its business leaders, have con- 
cluded that the rising percentage of the Gross Domestic 
Product for health care to more than 14% is unacceptable. 
Attempts to curb these increases through two major 
federal legislative initiatives, diagnosis related groups 
(DRGs) and resource-based relative value systems (RB- 
RVS), have clearly failed. 
New non-Medicare health insurance schemes based on 
the 1974 ERISA Act have resulted in the increasing preva- 
lence of health maintenance organizations (HMOs). Go- 
ing beyond clinical guidelines, HMOs have been empow- 
ered to introduce contracting, capitation, and other 
managed care mechanisms that many are coming to regard 
as being draconian. Meanwhile, and perhaps causally, the 
rate of growth of health care costs seems to be slowing. 
At a microeconomic level, new approaches such as case 
management and clinical pathways are being applied in- 
creasingly to rationalize resource utilization, optimize and 
hopefully improve patient care, and reduce financial costs. 
Dr. Muluk and his associates have reviewed their expe- 
rience with consecutive, nonurgent AAA operations over 3 
years. They found that thc institution of clinical pathways 
and case management, after a baseline year, produced a
decrease in hospital charges and overall LOS and a down- 
ward trend in mortality rates, which they suggested might 
be an indicator of improved patient care. By refining the 
pathway, further reductions in these parameters were 
achieved. Predictors of increased resource utilization were 
shown to be renal insufficiency and fluid overload. The cost 
and LOS, as well as the shape and content of their clinical 
pathway, which was also ldndly provided to me, resemble 
the information that we presented at one of the breakfast 
sessions of these meetings last year. 
Although the database and the number of measured 
parameters are small, the implications of this paper are 
enormous. Your decreasing trend in mortality rate was 
accompanied by a trend in decreased numbers of cases. 
Was this annual decline in utilization driven by capitation 
or other HMO forces? Was there a change in your aneu- 
rysm practice guidelines? Is it possible that your program 
to improve cost/benefit ratios may have led you to inter- 
vene on fewer and less-sick patients? You refer to costs, but 
measured charges with a disclaimer for inflation adjust- 
ment of charges. We all know that reliable cost data are 
nearly impossible to acquire. Has your cost-to-charge ratio 
remained constant over the 3-year period? Did the intro- 
duction of the pathway improve the net income of the 
hospital on this group of Medicare-age patients? In our 
hospital we have witnessed a small improvement in net 
income on DRG 110 (aneurysm) on noncapitated pa- 
tients, but this profit improvement does not extend to 
capitated patients within the overall case mix. We have 
used an in-house vascular extended care facility to reduce 
charges in these patients during the latter part of their 
hospitalization. Have you used this strategy? Might its 
application have obviated your observed increase the in 
readmiSsion rate? 
Finally, your group and ours achieved measurable im- 
provements in charge and LOS, but we differ in one critical 
aspect hat causes me deep concern. How has your cost- 
cutting program affected your educational mission? 
Same-day admissions deprive students and house offic- 
ers of the opportunity to perform preoperative workups, 
and in consequence d ny them the experience of learning 
to form meaningful doctor-patient relationships. Further- 
more, does the interpolation of a case manager curtail the 
house officer's autonomy and decision-making authority 
that is so essential to the development of clinical maturity? 
This paper is profoundly important for its host of practical 
and socioeconomic implications, and I thank the Society 
for the opportunity to discuss it. 
Dr. Satish C. Muluk. I will try to address your ques- 
tions one by one. Your first question related to the change 
in volume that we noted between groups II and III. I 
would note that group III constitutes a slightly smaller 
number of months--I  think it was 10 months--as opposed 
to the previous groups, which each covered 12 months. 
There was no real change in our indications for operating 
on aneurysm patients, so I can only attribute this change, 
which is relatively small, to fluctuations that we encounter 
on a regular basis in our practice. 
The other important issue is that of cost versus charges. 
Certainly we would have liked to have looked at actual 
cost, but, as you pointed out, it is extremely difficult to get 
actual cost information. What the hospital does provide is a 
cost-to-charge ratio, which allows us to get some rough 
estimate of cost. Using those cost-to-charge ratios would 
change our data slightly, but not in a major way over those 
3 years. We still find that our costs have declined in a 
similar fashion as I have depicted. The reason we chose to 
use charges, though, was that those numbers were more 
reliable, and we were not entirely clear where the cost-to- 
charge ratios were coming from. 
The third issue you raised was the issue of whether net 
DRG income has improved for the hospital for this diag- 
nosis. That is a very good question. I don't have the answer 
to that because we don't have that information from the 
hospital, but we will try to obtain that. 
Another important issue that you raise is that of the 
educational mission of the hospital. I don't know that the 
pathway is a critical issue in terms of affecting the educa- 
tional mission, but I think that certainly all of the other 
changes that are occurring are profoundly affecting the 
educational mission. We have tried to compensate for the 
fact that our residents cannot see the patients beforehand 
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by having them come on a regular basis to the office to see 
patients as at least a partial way of compensating for this 
problem. But I agree with you that focusing on the educa- 
tional mission is going to be a key issue as we make all of 
these changes. Unfortunately, it appears that the forces 
that are causing these changes are too powerful for us to 
really stop. 
Dr. Keith D. Calligaro (Philadelphia, Pa.). I would 
also like to congratulate Dr. Muluk and his associates from 
the University of Pittsburgh on an outstanding presenta- 
tion. On the other side of the state, in Philadelphia, our 
group previously reported results of implementation f 
clinical pathways for vascular surgery. We similarly recently 
analyzed patients who underwent aortoiliac surgery and 
there were about 70 patients in each group. We came to 
similar conclusions as your group did regarding the safety 
of shorter hospital LOS for these patients. 
I have two questions. What percent of patients who 
undergo aortic surgery could not be entered into your 
clinical pathways? You mentioned that you excluded pa- 
tients who required emergent surgery or had other factors. 
In our analysis, 20% of all patients could not be entered 
into clinical pathways. Those included patients who were 
transferred from other hospitals who at the time of arrival 
in our hospital had not undergone appropriate cardiac 
workup, or who were very sick and required other investi- 
gation, and therefore, obviously could not enter the same 
pathway as the people who were electively admitted the 
same day as their surgery. I think that it is important to 
document this so that third-party payers do not expect 
shorter hospital LOS and decreased costs for all patients 
who undergo aortic surgery. 
My second question is, how many of your patients in 
group III were admitted the same day as surgery? We have 
not found any increased morbidity rate with this change in 
strategy, although the concern exists regarding education 
for residents. But I agree with you, I doubt third-party 
payers are going to sacrifice admitting patients the day 
before surgery simply so our residents can see the patients. 
Dr. Muluk. The question about the percentage of 
aneurysm patients not entered into the study is an impor- 
tant one. Of patients who underwent elective aneurysm 
surgery, 98% were entered. The only ones who were ex- 
cluded were redo aneurysm patients and those who under- 
went another procedure, like a nephrectomy, for example, 
that was planned at the same time as the aneurysm surgery. 
The issue of patients being transferred from another 
hospital is a key one for us as well. We actually included 
those patients in the study if they were elective. And in- 
deed, our LOS figures are influenced by that. Our average 
LOS is indeed higher than our average LOS for patients 
who are admitted on a same-day basis for that reason. But 
we did want to include those patients in the pathway. So 
the pathway began at the moment hat the aneurysm 
surgery was decided on. 
On the issue of the same-day admission, we now have a 
high percentage ofour elective aneurysm patients coming 
in on a same-day basis. Of the elective aneurysm patients, 
roughly 80% come in the same day; the other 20% probably 
represent transfers from another institution. And that per- 
centage is about he same between groups II and III. It is 
slightly higher than the percentage for group I, which was 
about 70%. 
Dr. James C. Stanley (Ann Arbor, Mich.). Dr. Mu- 
luk, I would like to ask you a question about resource 
utilization and reimbursement, and the two are quite dif- 
ferent. At our institution we have looked at our 10 most 
common DRGs for vascular, and clearly identified some- 
thing like pulmonary edema or renal failure as something 
that drives an outlier very quick to the fringes of profitabil- 
ity for both the hospital, but not necessarily for the physi- 
cian, unless you have a capitated practice. The interesting 
thing is that about 15% of almost all managed care pro- 
grams will allow patients to be transferred out without 
significant penalty from their care. The smart group that 
does that will transfer out these very patients who you have 
identified that cost a great deal of money to the recipient 
hospital. The second is that your hospital cannot accept a 
patient, at least ours can't, if they go outside the Medicaid 
district hat they are initially assigned to. And that really 
jeopardizes a patient's care. Someone who has a thoraco- 
abdominal aneurysm, that's in renal failure, cannot leave 
the hospital that they have been admitted to, if there is a 
licensed vascular surgeon there, and come to your hospital 
if it's outside. Your hospital will not receive one penny. 
They can come, you just will never be reimbursed for it, 
not one cent. 
The issue with us, when we looked at the most domi- 
nant cause of three of our 10 DRGs that were the big 
money losers for our practice, was transfer. You could 
subdivide it and identify what these reasons were that they 
were transferred, i.e., renal failure, or they came in, they 
were intubated, in respiratory insufficiency or something. 
But the bottom line was transfer. And when I looked at 
your variables, you had not sorted that out. And I'm 
curious, have you looked at that? Because for a small 
percentage of us in this room that have big-time tertiary 
care practices, that's not going to be something our hospi- 
tals can afford as moneys get tighter. I 'm curious whether 
you have looked at that as a variable, even though it 
obviously has subvariables that we can define by logic 
terms. 
Dr. Mnluk. We have looked at the transfer group of 
patients, who represented roughly 20% in this population. 
Obviously some of the transferred patients, in fact many of 
them, were emergent and were therefore xcluded from 
this study. In Pennsylvania, the situation appears to be a 
little bit different in that when a patient is transferred, the 
recipient hospital gets the bulk of the DRG for that pa- 
tient. 
Dr. Stanley. Not with Medicaid. They may get it with 
other insurance carriers. 
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Dr. Muluk. To be honest, I am not sure of the details, 
but I think that applies to Medicare, at least in Pennsylva- 
nia, the way I've been told by our case manager. So that it 
actually is counterproductive for us, for example, to trans- 
fer a patient. Even if we transfer a patient in their last days 
before going to rehabilitation, our hospital would lose a 
good fraction of the DRG for that patient. 
Dr. John W. Hallett, Jr. (Rochester, Minn.). My 
question concerns the case manager concept, which you 
seemed to emphasize. Did you add a full-time equivalent 
to do this? Did you factor the salary and benefits of that 
position into your cost analysis? How essential do you 
think this case manager is in this type of process? 
Dr. Muluk. A very good question. We did not actually 
factor the salary of the case manager. They were provided 
by the hospital. Indeed, the case manager for vascular 
surgery covers not only vascular surgery but also transplant 
and general surgery. So our vascular surgery population is a 
relatively small fraction of her entire workload. But we do 
believe that the case manager concept is critical. Although 
we did not have the experience of using a pathway without 
a case manager, our information from other institutions 
was that it was virtually useless to impose a pathway be- 
cause of poor compliance, unless there was someone to 
monitor the compliance. 
We certainly did not allow the case manager to inter- 
fere with clinical decisions in cases where patients needed 
treatment for urgent problems. But her ole was more to 
perhaps guide the residents in terms of what laboratory 
studies and procedures were recommended forthe routine 
patient. 
Dr. Marvin A. McMillen (Chicago, Ill.). I 'm not sure 
there is really a huge difference between a clinical pathway 
and best clinical practice. And as a chief of surgery who 
happened to rain in medicine before going into surgery, I 
find that we can go to surgeons and get them to observe a
best clinical practice. As I review these issues in my own 
institution and try to break down the barriers between 
medicine and surgery, the problem actually seems to be 
our colleagues in medicine. Not only do these differences 
generate significant differences in LOS, but they also, un- 
fortunately, generate significant morbidity. I 'm curious 
what your involvement has been in the Department of 
Medicine, or do you just have total control of your vascular 
patients? What are your suggestions to the rest of us who 
oftentimes have a group of private primary care internists 
whose participation i the perioperative care of their pa- 
tients is sometimes a little more vigorous than we would 
like it to be? 
Dr. Muluk. A very good question. I think our degree 
of control over the aneurysm patients is such that we are 
able to enroll all of the patients into the pathway without 
any difficulty. There has been a little bit of resistance from 
the Department of Medicine at the University of Pitts- 
burgh for pathways, particularly for diagnoses like pneu- 
monia and chronic ventilator dependence. But for even 
those diagnoses, now, pathways are being developed, at a 
slower rate perhaps though than for many of the surgical 
procedures, for which we now have over a hundred path- 
ways established. 
Dr. Stephen P. Murray (San Antonio, Tex.). I ap- 
plaud your efforts in showing the Society the benefits of 
instituting quality improvement in a fashion similar to that 
espoused by Dr. Goldstone in his address. My question has 
to do with implementation. 
I continue to be amazed how contentious the issue of 
fluid management is in our postoperative patients as evi- 
denced by the battles that occur at our morning reports 
between intensivists and surgeons. You would think that 
after so many ears of dealing with this we would have fixed 
that problem long ago. 
In your objective analysis you used CXR. My first 
question ishow did you arrive at using a CXRto determine 
pulmonary edema given the plethora of other measures 
available--patient weight, Swan-Ganz data, etc.--and 
were the assessments of pulmonary edema on those CXRs 
read in a blinded fashion? 
Second, once you determine the optimal method for 
determining this fluid overload, how did you bring on your 
colleagues in anesthesia and in the ICU so as to best come 
to an agreement on what would be the best means of 
resuscitating the patient during and after surgery? Who, in 
other words, was in control practically and could dictate 
turning the fluid up or down down, giving Lasix, not 
giving Lasix? 
Dr. Mttluk. The CXR criteria were picked really be- 
cause of the ease of use. We were easily able to retrieve 
CXR data from the computerized database, more easily, 
for example, than central pressures or patient weight. Al- 
though we could have retrieved those data, it would have 
been more difficult for us. And we believed that the CXR 
was somewhat more objective as long as the same standards 
were applied throughout. And indeed, the study was 
blinded to the extent that the radiologists really had no 
idea of the progression of the pathway when they were 
reading the studies. Studies were routinely read in the ICU 
x-ray suite. 
The involvement of the anesthesiologists and the 
ICU staffwas critical. They were actually involved from 
the very beginning in the development of the pathway, 
so it was not particularly difficult to get them to change 
their practice. It's actually been remarkable, after look- 
ing at objective data, how willing they were to change 
their method of fluid administration a d to really restrict 
fluid administration so as to keep the urine output ade- 
quate in these patients. 
Dr. Jerry Goldstone (San Francisco, Calif.). I just 
want to make a couple of comments and emphasize a
couple of things. These practice guidelines, or whatever 
you choose to call them, are dynamic, they change. And 
the whole concept here is that you develop a system that 
you think is the best possible care and then you keep 
studying it and you keep making it better, little by little. I 
think everybody has the idea that once these guidelines are 
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written down they are carved in stone. But they're not. The 
purpose is to keep changing it, to keep making it better; 
again, you continuously improve it. 
Referring to the question about education, in all these 
things you can set up a system whereby people can work 
outside the guidelines. The educational component comes 
when you make everybody document why they are doing 
that and then you discuss these things in a nonpunirive 
way. Every once in a while you'll find that somebody will 
deviate from a guideline because they've got a good idea 
that you haven't thought of before. So again, I think the 
message here is that this is a continuous process, you've got 
to keep doing it, make it better, little by little, all the time. 
As the Japanese say, "kaizen." 
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